- Investing Ideas
- U.S. Pharmaceuticals & Biotech Buy the Dip
U.S. Pharmaceuticals & Biotech Buy the Dip
Results
39
Companies which have seen a dip in the last 7 days after continued gains and are looking undervalued based on Snowflake checks.
39 companies
Arrowhead Pharmaceuticals
Market Cap: US$10.1b
Develops medicines for the treatment of intractable diseases in the United States.
ARWR
US$71.82
7D
-16.2%
1Y
292.5%
ImmunityBio
Market Cap: US$8.3b
A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
IBRX
US$7.73
7D
-12.2%
1Y
181.1%
PTC Therapeutics
Market Cap: US$6.5b
A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
PTCT
US$78.84
7D
-11.0%
1Y
63.8%
Celcuity
Market Cap: US$5.4b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$91.51
7D
-16.0%
1Y
560.2%
NewAmsterdam Pharma
Market Cap: US$3.9b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$31.98
7D
-10.7%
1Y
52.9%
Tarsus Pharmaceuticals
Market Cap: US$2.4b
A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
TARS
US$57.50
7D
-15.1%
1Y
38.4%
Mineralys Therapeutics
Market Cap: US$2.4b
A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
MLYS
US$27.31
7D
-10.2%
1Y
90.7%
AnaptysBio
Market Cap: US$1.9b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$55.82
7D
-14.6%
1Y
107.8%
Stoke Therapeutics
Market Cap: US$1.8b
Engages in the development of treatments for severe genetic diseases by upregulating protein expression.
STOK
US$29.91
7D
-8.4%
1Y
151.3%
Capricor Therapeutics
Market Cap: US$1.2b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$20.35
7D
-8.5%
1Y
181.1%
MeiraGTx Holdings
Market Cap: US$1.2b
A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
MGTX
US$12.56
7D
-11.2%
1Y
44.9%
Solid Biosciences
Market Cap: US$948.1m
Develops therapies for neuromuscular and cardiac diseases in the United States.
SLDB
US$9.62
7D
-12.5%
1Y
72.4%
Arbutus Biopharma
Market Cap: US$910.6m
A clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
ABUS
US$4.56
7D
-12.6%
1Y
45.7%
Phathom Pharmaceuticals
Market Cap: US$876.5m
A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
PHAT
US$11.05
7D
-8.4%
1Y
32.7%
Design Therapeutics
Market Cap: US$853.8m
A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
DSGN
US$13.52
7D
-11.5%
1Y
225.8%
Ironwood Pharmaceuticals
Market Cap: US$655.2m
A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
IRWD
US$4.00
7D
-16.1%
1Y
440.8%
Allogene Therapeutics
Market Cap: US$638.5m
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
ALLO
US$1.90
7D
-10.4%
1Y
54.5%
REGENXBIO
Market Cap: US$635.4m
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
RGNX
US$12.27
7D
-19.4%
1Y
44.4%
4D Molecular Therapeutics
Market Cap: US$611.6m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$11.68
7D
-10.3%
1Y
174.2%
Kyverna Therapeutics
Market Cap: US$482.7m
A late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
KYTX
US$7.78
7D
-21.5%
1Y
91.2%
Ovid Therapeutics
Market Cap: US$459.1m
A biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
OVID
US$2.49
7D
-8.8%
1Y
538.5%
Prothena
Market Cap: US$452.3m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$8.43
7D
-14.4%
1Y
33.4%
Prelude Therapeutics
Market Cap: US$435.4m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$4.46
7D
-12.9%
1Y
443.8%
Cabaletta Bio
Market Cap: US$435.4m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$2.77
7D
-11.5%
1Y
63.9%
Sutro Biopharma
Market Cap: US$431.3m
Operates as an oncology company.
STRO
US$26.00
7D
-18.3%
1Y
243.6%
Century Therapeutics
Market Cap: US$384.2m
A biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
IPSC
US$2.17
7D
-10.7%
1Y
262.9%
Enanta Pharmaceuticals
Market Cap: US$381.2m
A biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
ENTA
US$13.23
7D
-8.7%
1Y
86.6%
Opus Genetics
Market Cap: US$293.9m
A clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
IRD
US$3.48
7D
-15.1%
1Y
210.7%
ALX Oncology Holdings
Market Cap: US$269.1m
A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
ALXO
US$2.03
7D
-12.9%
1Y
334.7%
Karyopharm Therapeutics
Market Cap: US$226.9m
A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
KPTI
US$9.53
7D
-10.7%
1Y
128.0%
Coherus Oncology
Market Cap: US$223.7m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.44
7D
-12.7%
1Y
60.0%
Nkarta
Market Cap: US$189.6m
A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
NKTX
US$2.66
7D
-27.5%
1Y
45.4%
Acumen Pharmaceuticals
Market Cap: US$182.7m
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
ABOS
US$2.22
7D
-18.7%
1Y
60.9%
Pyxis Oncology
Market Cap: US$145.1m
A clinical stage company, engages in the development of therapeutics to treat solid tumors.
PYXS
US$2.43
7D
-9.7%
1Y
104.2%
Burning Rock Biotech
Market Cap: US$104.8m
Develops and sells cancer therapy selection tests in the People's Republic of China and the United States.
BNR
US$9.30
7D
-20.9%
1Y
102.2%
Cognition Therapeutics
Market Cap: US$90.4m
A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
CGTX
US$0.95
7D
-11.3%
1Y
53.9%